FORM 4
< > Check this box if no longer
|
FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES |
OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5 |
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
| 1. Name and Address of Reporting Person *
Empire Capital Management, L.L.C. |
2. Issuer Name and Ticker or Trading Symbol
SONUS NETWORKS INC [ SONS ] |
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)
_____ Director __ X __ 10% Owner _____ Officer (give title below) _____ Other (specify below) |
| (Last) (First) (Middle)
1 GORHAM ISLAND, SUITE 201 |
3. Date of Earliest Transaction (MM/DD/YYYY)
10/24/2012 |
| (Street)
WESTPORT, CT 06880 (City) (State) (Zip) |
4. If Amendment, Date Original Filed (MM/DD/YYYY)
|
6. Individual or Joint/Group Filing (Check Applicable Line)
___ Form filed by One Reporting Person _ X _ Form filed by More than One Reporting Person |
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned |
1.Title of Security (Instr. 3) |
2. Trans. Date |
2A. Deemed Execution Date, if any |
3. Trans. Code (Instr. 8) |
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) |
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) |
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) |
7. Nature of Indirect Beneficial Ownership (Instr. 4) |
| Code |
V |
Amount |
(A) or (D) |
Price |
| Common Stock, $0.001 par value |
10/24/2012 |
|
P |
|
105000 |
A |
$1.80 |
37860000 |
I |
See Notes (1) (2) (3) (4) (5) |
| Common Stock, $0.001 par value |
10/25/2012 |
|
P |
|
212974 |
A |
$1.79 |
38072974 |
I |
See Notes (1) (2) (3) (4) (5) |
| Common Stock, $0.001 par value |
10/26/2012 |
|
P |
|
19700 |
A |
$1.80 |
38092674 |
I |
See Notes (1) (2) (3) (4) (5) |
Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) |
1. Title of Derivate Security (Instr. 3) |
2. Conversion or Exercise Price of Derivative Security |
3. Trans. Date |
3A. Deemed Execution Date, if any |
4. Trans. Code (Instr. 8) |
5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) |
6. Date Exercisable and Expiration Date |
7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) |
8. Price of Derivative Security (Instr. 5) |
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) |
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) |
11. Nature of Indirect Beneficial Ownership (Instr. 4) |
| Code |
V |
(A) |
(D) |
Date Exercisable |
Expiration Date |
Title |
Amount or Number of Shares |
| Explanation of Responses: |
| ( 1) |
This statement is filed by Empire Capital Management, LLC, a Delaware limited liability company (Empire Management) with respect to the shares of Common Stock directly held by Empire Capital Partners, LP (Empire Onshore), Empire Capital Partners, LTD (Empire Offshore), Empire Capital Partners Enhanced Master Fund, LTD (Empire Enhanced Master, and together, the Empire Investment Funds) and Charter Oak Partners LP, Charter Oak Partners II LP and Charter Oak Master Fund Ltd (together, the Empire Sub-Advised Funds). |
| ( 2) |
Mr. Fine and Mr. Richards are the only Managing Members of Empire Management. |
| ( 3) |
Mr. Fine disclaims beneficial ownership of the shares of Common Stock reflected in this filing, except with respect to any pecuniary interest in such securities. |
| ( 4) |
Mr. Richards disclaims beneficial ownership of the shares of Common Stock reflected in this filing, except with respect to any pecuniary interest in such securities. |
| ( 5) |
Empire Capital respectfully submits this filing with a slight delay due to the recent hurricane. |
Reporting Owners |
| Reporting Owner Name / Address |
Relationships |
| Director |
10% Owner |
Officer |
Other |
Empire Capital Management, L.L.C. 1 GORHAM ISLAND SUITE 201 WESTPORT, CT 06880 |
|
X |
|
|
Fine Scott A C/O EMPIRE CAPITAL MANAGEMENT LLC 1 GORHAM ISLAND, SUITE 201 WESTPORT, CT 06880 |
|
X |
|
|
Richards Peter J C/O EMPIRE CAPITAL MANAGEMENT LLC 1 GORHAM ISLAND, SUITE 201 WESTPORT, CT 06880 |
|
X |
|
|
Signatures |
| /s/ Scott A Fine, individually and as Managing Member of Empire Capital Management, LLC /s/ Peter J Richards, individually and as Managing Member of Empire Capital Management, LLC |
|
10/31/2012 |
| ** Signature of Reporting Person |
Date
|
| Scott A Fine |
|
10/31/2012 |
| ** Signature of Reporting Person |
Date
|
| Peter J Richards |
|
10/31/2012 |
| ** Signature of Reporting Person |
Date
|
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. |
| * |
If the form is filed by more than one reporting person, see Instruction 4(b)(v). |
| ** |
Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
| Note: |
File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. |
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. http://investors.sonusnet.com/secfiling.cfm?f...IK=1105472 |
Sonus Networks (SONS) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
SVRN Aims for New Heights with a Savvy Hire If there’s one thing veteran market-watchers like myself know, it’s that leadership shifts can tell you more about a company’s guts than any press release. SVRN (NASDAQ: SVRN), a name with one foot firmly in the world of digital assets, just snagged Patrick O’Kain for their COO spot. They're not playing around, folks,...
Continue Reading
Midterms and 'Trump Derangement Syndrome': What's the Deal? Every election season there's something new to raise eyebrows, and this time it's 'Trump Derangement Syndrome' (TDS) taking the spotlight. After the dust of the 2026 mid-terms started settling, it turns out there's more than just traditional candidate bickering shaping votes. Can you guess what's driving voters?...
Continue Reading
Strong Q3 Numbers Set the Scene It’s not every day you see a company cough up numbers that speak volumes. Sempra’s third quarter for 2026 paints a picture of solid performance, boasting earnings of $877 million or $1.34 per diluted share per GAAP standards. That’s an eye-opener compared to the paltry $77 million or $0.12 per share they reported same time last year....
Continue Reading
Securities Law Tangles: Coastal Financial Hits a Snag There's no dodging it—Coastal Financial Corporation's dogged by a class action lawsuit, and investors need to sit up and take notice. This kind of legal fracas can hit the stock price like a brick through a window, especially when alleged securities law violations crop up. DJS Law Group's got the reins on this one,...
Continue Reading
Shuffling Pieces in Healthcare Management Change is constant in healthcare management, folks, and it's all about finding the right puzzle pieces. That's what Assembly Health has done by welcoming Grant Davis as their new Chief Experience Officer (CXO). Yeah, you heard me right. It's not a CEO or a CFO, but the CXO role that's under the spotlight this time around, aiming...
Continue Reading
Brooklyn's Gem: MAURE Turns Three Over in Brooklyn, there's a brand bubbling with style called MAURE. Now, we're talking three years strong, surviving the wild bout of the retail scene with a firm two feet planted in home and gifting. The Vision Turned Reality When Maureen Cavalieri, a hospitality veteran since 2009, first tossed this spark into the wind in 2023, it...
Continue Reading
Pushing the Horizons in Hematological Research From the bustling streets of Shanghai to the global stage of the ASH 2026, Dizal has made its mark again. This year's presentations could very well shake up the hematological landscape, showcasing new possibilities for treatment strategies. Golidocitinib: A Game-Changer? Now here's a ticket we've been watching with some high...
Continue Reading
Pardon my skepticism, but when a roofing company names itself Life of Abundance, you know they're aiming to hit it big or at least make you think they're onto something special. LOA Roofing and Construction, holding its ground as a major player in the Central Texas market, set the stage for more ambitious growth. And they found themselves a dance partner in Southstone...
Continue Reading
SKF's Green Initiative: A Major Step Forward You ever find yourself in a room full of big players, each trying to outdo the other? That's the stage set for SKF at COP31, where they're not just strutting around showing off but actually offering some substance—a rarity in these highbrow gatherings. They're juicing up the talk around energy efficiency and circularity...
Continue Reading
Unpacking Lilly's Latest Rheumatology Innovations Lilly's taking the stage at ACR Convergence 2026 with a potent arsenal of data that’s got folks buzzing. The company’s put the pedal to the metal on understanding the intertwining chords of obesity and rheumatologic conditions, and boy, are they not messing around. Retatrutide: A Triple Threat in the Making Headlining...
Continue Reading
Top 5 Most Recently Viewed Articles
SKYX Technologies' Corporate Developments SKYX Technologies, also known as SKYX (NASDAQ: SKYX), is taking significant strides in the smart technology sector. This dynamic company focuses on transforming homes and buildings into smarter, safer, and more advanced spaces. With a remarkable portfolio of over 97 issued and pending patents, SKYX aims to set a new standard in...
Continue Reading
Crinetics Pharmaceuticals Enhances Employee Incentives In a recent announcement, Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX), based in San Diego, revealed a significant step in enhancing employee incentives and strengthening its workforce. On October 10, 2025, the company’s Compensation Committee authorized the granting of stock options and restricted stock units...
Continue Reading
Manulife Investment Management Recognized for Excellence In a significant acknowledgment of its leadership in sustainable finance, Manulife Investment Management (Manulife IM) has made it to the prestigious list of IPE Real Assets' Top 50 Natural Capital Managers. This recognition comes as the firm is gearing up for robust fundraising activities, with an exciting fund...
Continue Reading
Vaxart’s Business Progress and Financial Results Overview Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company, recently provided a significant update on its business and reported its financial outcomes for the third quarter of 2025. This latest communication showcases exciting developments in their oral recombinant vaccine platform, which is designed to...
Continue Reading
Madrigal Pharmaceuticals Achieves Enrollment Milestone in NASH Study Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company dedicated to developing innovative therapies for liver diseases, has announced a significant milestone in their MAESTRO-NASH OUTCOMES clinical trial. This study evaluates the efficacy of resmetirom in patients diagnosed with...
Continue Reading